Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 601–700 of 1,006
Jeong, S. Y., Suh, C. H., Shim, W. H., Lim, J., Lee, J., & Kim, S. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201019 · Cited by 60
“001; Figures 2 and 3) compared with other agents.(15-34)”
BackgroundMethodResultInfluentialQiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
“The incidence of ARIAs was 0.9% and 0.4% for solanezumab and placebo, respectively, indicating that solanezumab did not induce ARIAs, thus displaying its great tolerability and safety [38].”
InfluentialEvolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 42
Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model
Dorostkar, M. M., Burgold, S., Filser, S., Barghorn, S., Schmidt, B., Anumala, U. R., Hillen, H., Klein, C., & Herms, J. (2014) · Brain · doi:10.1093/brain/awu280 · Cited by 38
Dai, H., Hu, W.-Y., Jiang, L.-H., Li, L., Gaung, X., & Xiao, Z. (2016) · Scientific Reports · doi:10.1038/srep27600 · Cited by 40
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H.-H., Yin, W., Lin, B., Fan, W.-B., Zhang, X., & Fernandez-Funez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 35
Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease
Chakravarthy, M., Chen, S., Dodd, P. R., & Veedu, R. N. (2017) · Theranostics · doi:10.7150/thno.21529 · Cited by 44
“Solanezumab Aβ aggregation inhibitor Phase III End points not significantly improved [56]”
BackgroundThe potential of memory enhancement through modulation of perineuronal nets
Duncan, J. A., Foster, R., & Kwok, J. C. F. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14672 · Cited by 38
“Several anti‐Aβmonoclonal antibody therapies (Doody et al., 2014; Vandenberghe et al., 2016) and a selection of β‐secretase (BACE1) inhibitors (Vassar, 2014) have progressed as far as phase III clinical trials but have failed to translate into commercial medicines.”
BackgroundZeng, Q., Li, L., Yu, J., Chen, Z., Duan, L., Cao, M., Ma, M., & Wu, Z. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/8706589 · Cited by 51
Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques
Ezzati, A., Harvey, D. J., Habeck, C. G., Golzar, A., Qureshi, I., Zammit, A. R., Hyun, J., Truelove‐Hill, M., Hall, C. B., Davatzikos, C. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191038 · Cited by 38
Bullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“Although the biomarker data in phase II demonstrated dose-dependent changes, in phase III testing, there was no significant change on several clinical outcomes, including ADAS-Cog11, ADCS-ADL, CDR-SB, NPI, and MMSE, following treatment with solanezumab (Doody et al., 2014).”
InfluentialSelf-citationHao, L., Sun, Y., Li, Y., Wang, J., Wang, Z., Zhang, Z., Wei, Z., Gao, G., Jia, J., Xing, Y., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51068 · Cited by 39
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
Baidya, F., Bohra, M., Datta, A., Sarmah, D., Shah, B., Jagtap, P., Raut, S., Sarkar, A., Singh, U., Kalia, K., et al. (2021) · Immunology · doi:10.1111/imm.13264 · Cited by 38
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 42
“A well-known example from AD is monitoring for amyloid-related imaging abnormalities (ARIA) [5, 12, 90, 128, 129].”
BackgroundInsulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 42
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Yi, L., Tan, E. K., & Zhou, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05248-x · Cited by 49
“Two previous phase III clinical trials using solanezumab also showed negative results [1, 5, 6].”
BackgroundA β-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu-Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 37
Walsh, C., Drinkenburg, W. H. I. M., & Ahnaou, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.020 · Cited by 39
Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
Menéndez‐González, M., Padilla-Zambrano, H., Alvarez, G., Capetillo‐Zarate, E., Tomás‐Zapico, C., & Costa, A. D. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00100 · Cited by 39
“Authors also observed a decrease in tau hyperphosphorylation, an increase in the number of microglia counts and an improved learning behavior (Doody et al., 2014).”
BackgroundTau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novak, P., Cehlar, O., Skrabana, R., & Novak, M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179942 · Cited by 37
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
Willis, B. A., Sundell, K., Lachno, D. R., Ferguson‐Sells, L. R., Case, M. G., Holdridge, K., DeMattos, R. B., Raskin, J., Siemers, E. R., & Dean, R. A. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.001 · Cited by 37
“Solanezumab did not significantly reduce cognitive or functional decline in a pooled analysis of patients ranging from mild to moderate AD dementia [4]; however, in a prespecified, pooled secondary analysis, patients with mild AD dementia treated with solanezumab showed less cognitive (approximately 34%) and functiona…”
BackgroundResultInfluentialSelf-citationAnsart, M., Epelbaum, S., Gagliardi, G., Colliot, O., Dormont, D., Dubois, B., Hampel, H., Durrleman, S., & study, F. T. A. D. N. I. A. T. I.-P. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280218823036 · Cited by 37
“6 Several of these drugs, such as solanezumab 7 and bapineuzumab, 8 have been tested on individuals with dementia or with mild cognitive impairments, but did not result in a decrease of the cognitive decline.”
Li, X., Lu, J., Xu, Y., Wang, J., Qiu, X., Fan, L., Li, B., Liu, W., Mao, F., Zhu, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.006 · Cited by 40
“4-Bromo-2-hydroxy-N-(5-morpholinothiazol-2-yl) benzamide (17) 17 was synthesized by the general procedure of 15 given above, 4fluoro-2-hydroxybenzoic acid was replaced by 4-bromo-2hydroxybenzoic acid, to afford 17 as a brown solid.”
MethodFlotillin is a Novel Diagnostic Blood Marker of Alzheimer’s Disease
Abdullah, M., Kimura, N., Akatsu, H., Hashizume, Y., Taslima, F., Tachita, T., Iida, S., Zou, K., Matsubara, E., & Michikawa, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190908 · Cited by 36
Schnöder, L., Gasparoni, G., Nordström, K. J. V., Schottek, A., Tomic, I., Christmann, A., Schäfer, K. H., Menger, M. D., Walter, J., Fassbender, K. C., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902731rr · Cited by 41
Wang, J., Cunningham, R., Zetterberg, H., Asthana, S., Carlsson, C. M., Okonkwo, O. C., & Li, L. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600009 · Cited by 38
“Specifically, the recently reported failure of a phase 3 clinical trial of humanized monoclonal antibody of soluble forms of amyloid [9, 10] necessitates the discovery and establishment of other biomarkers and targets for disease diagnosis, prevention, and/or treatment.”
BackgroundImplications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 40
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“[129–131].”
Association between alcohol and Alzheimer's disease
Huang, W., Zhang, X., & Chen, W. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3455 · Cited by 39
Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease
Kim, Y. H., Lee, S.-M., Cho, S., Kang, J., Minn, Y., Park, H., & Choi, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41429-1 · Cited by 40
Foroutan, N., Hopkins, R. B., Tarride, J., Flórez, I. D., & Levine, M. (2019) · Clinical and investigative medicine · doi:10.25011/cim.v42i1.32393 · Cited by 38
N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 37
Xu, Y., Zhao, M.-N., Zhou, D., Zheng, T., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111360 · Cited by 38
Defective Autophagy and Mitophagy in Alzheimer’s Disease: Mechanisms and Translational Implications
Chen, J., He, H., Ye, Q., Feng, F., Wang, W., Gu, Y., Han, R., & Xie, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02487-7 · Cited by 37
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Puente, O. A., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., KIPROV, D. D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12477 · Cited by 40
AbdAlla, S., Hakim, A., Abdel-Baset, A., el Faramawy, Y., & Quitterer, U. (2015) · BioMed Research International · doi:10.1155/2015/917156 · Cited by 42
Translational strategies in aging and age-related disease
Armanios, M., de Cabo, R., Mannick, J., Partridge, L., van Deursen, J., & Villeda, S. (2015) · Nature Medicine · doi:10.1038/nm.4004 · Cited by 36
Li, Q., Peng, J., Luo, Y., Zhou, J., Li, T., Cao, L. S., Peng, S., Zuo, Z., & Wang, Z. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02521-y · Cited by 38
Artificial intelligence for neurodegenerative experimental models
Marzi, S. J., Schilder, B. M., Nott, A., Frigerio, C. S., Willaime‐Morawek, S., Bucholc, M., Hanger, D. P., James, C., Lewis, P. A., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13479 · Cited by 35
“To improve reproducibility, and to allow the identification and further investigation of key background genetic modifiers of the dis-easephenotype,ideallysequencingshouldberepeatedafterextensive backcrossingbyacademiclaboratories,andifmicearebredtocongenic lines by commercial suppliers.”
BackgroundAnti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA
Sin, M., ZAMRINI, E. Y., Ahmed, A., Nho, K. T., & Hajjar, I. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216792 · Cited by 44
“For example, several clinical trials have reported an ARIA-E incidence of up to 55% in ApoE e4 (homozygous) carriers receiving the N-terminus amyloid β targeted medications [32,49,50] compared to treatments targeting the mid-domain or C-terminus of amyloid β [51,52].”
BackgroundWu, J., Yu, H., Bi, S.-G., Wang, Z., Gong, J., Mao, Y.-M., Wang, F., Zhang, Y., Nie, Y., & Chai, G. (2023) · Autophagy · doi:10.1080/15548627.2023.2281134 · Cited by 40
“However, most of them fail to attenuate cognitive deficits and cause side effects, including neuroinflammation and other neuropathologies [4,5].”
BackgroundLee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
“Anti-A β immunotherapy has been shown to reduce the amyloid burden in AD mouse models and also in the clinic for human trials 106 – 112 .”
Nonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Amyloid beta peptide immunotherapy in Alzheimer disease
Delrieu, J., Ousset, P., Voisin, T., & Vellas, B. J. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.003 · Cited by 39
Self-citationBiomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
Insel, P. S., Mattsson, N., Mackin, R. S., Kornak, J., Nosheny, R. L., Tosun, D., Donohue, M., Aisen, P. S. S., Weiner, M. W., & Initiative, A. D. N. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.192 · Cited by 35
Self-citationAberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 40
“A phase 3 study of solanezumab showed no improvement on the primary outcomes of mild-to-moderate AD patients, but slowed cognitive decline in mild AD patients [Doody et al., 2014].”
BackgroundGuo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 39
Trazodone use and risk of dementia: A population-based cohort study
Brauer, R., Lau, W. C. Y., Hayes, J. F., Man, K. K. C., Osborn, D. P. J., Howard, R., Kim, J., & Wong, I. C. K. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002728 · Cited by 35
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Why Inclusion Matters for Alzheimer’s Disease Biomarker Discovery in Plasma
Khan, M. J., Desaire, H., López, O. L., Kamboh, M. I., & Robinson, R. A. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201318 · Cited by 36
“Currently,African American/Blackadultsparticipateinclinicaltrials atarateof ∼ 5% and in AD research assessments at ∼ 13% [25–27].”
Wessels, A. M., Dennehy, E. B., Dowsett, S. A., Dickson, S. P., & Hendrix, S. B. (2023) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200127 · Cited by 35
“This investment was driven by the inconsistent performance of outcome measures at this stage of disease.(6,7)”
MethodAlzheimer’s disease progression by geographical region in a clinical trial setting
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu-Seifert, H., Grill, J. D., Doody, R. S., Aisen, P., Raman, R., Miller, D. S., Hake, A. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0127-0 · Cited by 35
Self-citationKorábečný, J., Špilovská, K., Mezeiová, E., Benek, O., Jůza, R., Kaping, D., & Soukup, O. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180517094023 · Cited by 40
Yoon, G., Shah, S. A., Ali, T., & Kim, M. O. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0847-1 · Cited by 34
“Therapeutic approaches targeting Aβ have been applied to halt disease progression, but satisfactory consequences remain limited because cognitive improvement was not completely attained [6].”
BackgroundLessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 40
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Li, J., Liao, W., Huang, D., Ou, M., Chen, T., Wang, X., Zhao, R., Zhang, L., Mei, L., Liu, J., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215375 · Cited by 38
Andreasen, N., Simeoni, M., Ostlund, H., Lisjo, P. I., Fladby, T., Loercher, A. E., Byrne, G. J., Murray, F., Scott-Stevens, P. T., Wallin, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0098153 · Cited by 34
Rauth, S., Hinz, D., Borger, M. A., Uhrig, M., Mayhaus, M., Riemenschneider, M. J., & Skerra, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160114 · Cited by 39
Linking multiple pathogenic pathways in Alzheimer’s disease
Khalil, R. B., Khoury, E., & Koussa, S. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i2.208 · Cited by 38
A refined concept: α-synuclein dysregulation disease
Mochizuki, H., Choong, C., & Masliah, E. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.011 · Cited by 37
“However, the first phase 3 trials of solanezumab for mild-to-moderate AD showed that the antibody failed to improve cognition or functional ability (EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683) (Doody et al., 2014).”
Rationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 33
“though it did appear to slow the decline in cognition in the subset of AD patients who had mild AD.(21,29,56,57,60) However, a subsequent trial in prodromal AD showed no effect on cognitive decline.”
BackgroundInfluentialCurrent and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
Cselényi, Z., & Farde, L. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.66 · Cited by 34
Li, C., Guo, X., Lei, M., Wu, J., Jin, J.-Z., Shi, X., Zhu, Z., Rukachaisirikul, V., Hu, L., Wen, T., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.94 · Cited by 36
Liu, M., Jevtic, S. D., Markham-Coultes, K., Ellens, N. P. K., O’Reilly, M. A., Hynynen, K., Aubert, I., & McLaurin, J. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.015 · Cited by 37
Shastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 36
Wang, T., Xie, X.-X., Ji, M., Wang, S., Zha, J., Zhou, W.-W., Yu, X., Chen, W., Ma, S., Xi, Z.-Y., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.015 · Cited by 36
DeBay, D. R., Reid, G. A., Macdonald, I. R., Mawko, G., Burrell, S., Martin, E. V., Bowen, C. V., & Darvesh, S. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.009 · Cited by 37
Chang, K. L., Wong, L. R., Pee, H. N., Yang, S., & Ho, P. C. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1586-2 · Cited by 35
Clinical trials of prion disease therapeutics
Forloni, G., Roiter, I., & Tagliavini, F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.019 · Cited by 37
Application of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 40
Are extracellular vesicles new hope in clinical drug delivery for neurological disorders?
Muhammad, S. A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104955 · Cited by 34
Groot, C., Grothe, M. J., Mukherjee, S., Jelistratova, I., Jansen, I. E., van Loenhoud, A. C., Risacher, S. L., Saykin, A. J., Donald, C. L. M., Mez, J., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102660 · Cited by 33
“…MMSE was selected to measure global cognition and progression as it is a widely implemented test to examine clinical progression in clinical practice (Doody et al., 2001) and clinical trials (Doody et al., 2014; Salloway et al., 2014), and is administered at every follow-up visit in the ADC cohort.”
BackgroundMethodBullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01048-x · Cited by 34
“With the negative outcomes of several therapeutic clinical trials in reducing the cognitive decline in mild-to-moderate AD [17, 18], investigators were encouraged to explore treatment effects in the earliest possible phase of biomarkers abnormalities event at the asymptomatic stage.”
BackgroundHong, Z., Yu, S., Wang, Z., & Zhu, Y. Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818544 · Cited by 36
Shin, J.-W., An, S., Kim, D., Kim, H., Ahn, J.-H., Eom, J., You, W., Yun, H., Lee, B., Sung, B., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100338 · Cited by 40
“Engineering monoclonal antibodies (mAbs) to target and neutralize neurotoxic proteinaceous species has emerged as one of the most promising strategies for treating both Alzheimer’s disease (AD) (Bittar et al., 2020; Doody et al., 2014; Sevigny et al., 2016; van Dyck, 2018) and Parkinson’s disease (PD) (Chatterjee and…”
BackgroundMahaman, Y. A. R., Huang, F., Salissou, M. T. M., Yacouba, M. B. M., Wang, J., Liu, R., Zhang, B., Li, H., Zhu, F., & Wang, X. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01356-6 · Cited by 35
“Despite decades of research in the field of AD, no cure exists for this debilitating disease, and many of the Aβ- and tau-targeted therapies have failed [21, 22, 98, 99], thus leaving clinicians with limited management strategies.”
BackgroundCerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 40
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 38
Leaver, K. R., & Poston, K. L. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9307-8 · Cited by 35
Targeting β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes
Liu, H., Yang, J., Wang, L., Xu, Y., Zhang, S., Lv, J., Ran, C., & Li, Y. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0185 · Cited by 33
Single-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide
Käkinen, A., Xing, Y., Arachchi, N. D. H., Javed, I., Feng, L., Faridi, A., Douek, A. M., Sun, Y., Kaslin, J., Davis, T. P., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02771 · Cited by 32
West Nile Virus-Induced Neurologic Sequelae—Relationship to Neurodegenerative Cascades and Dementias
Vittor, A. Y., Long, M. T., Chakrabarty, P., Aycock, L., Kollu, V., & DeKosky, S. T. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00200-7 · Cited by 36
Abate, G., Vezzoli, M., Polito, L., Guaita, A., Albani, D., Marizzoni, M., Garrafa, E., Marengoni, A., Forloni, G., Frisoni, G. B., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm11010014 · Cited by 32
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies
Wasan, H., Singh, D., & Kh, R. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.018 · Cited by 34
Decourt, B., Noorda, K., Noorda, K. J., Shi, J., & Sabbagh, M. N. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265626 · Cited by 34
“Initial results from the Expedition 1 (NCT00905372) and Expedition 2 (NCT00904683) Phase III trials did not show significant clinical improvements in participants treated for 18 months with solanezumab.(130) However, a later complementary data analysis discovered a slowing in cognitive and functional deterioration in…”
Specific Amyloid β Clearance by a Catalytic Antibody Construct
Planque, S. A., Nishiyama, Y., Sonoda, S., Lin, Y., Taguchi, H., Hara, M., Kolodziej, S. J., Mitsuda, Y., González‐Calle, V., Sait, H. B. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641738 · Cited by 32
Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 33
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
Li, C., Zhou, L., & Yin, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342181 · Cited by 41
Insights into Mechanisms of Chronic Neurodegeneration
Diack, A. B., Alibhai, J. D., Barron, R. M., Bradford, B. M., Piccardo, P., & Manson, J. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010082 · Cited by 34
Multimorbidity Is Associated with Preclinical Alzheimer’s Disease Neuroimaging Biomarkers
Mendes, A., du Montcel, S. T., Lévy, M., Bertrand, A., Habert, M., Bertin, H., Dubois, B., Epelbaum, S., & INSIGHT-PreAD study group (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000489007 · Cited by 35
Emerging Approaches to Investigate the Influence of Transition Metals in the Proteinopathies
Lermyte, F., Everett, J. L., Brooks, J., Bellingeri, F., Billimoria, K., Sadler, P. J., O’Connor, P. B., Telling, N. D., & Collingwood, J. F. (2019) · Cells · doi:10.3390/cells8101231 · Cited by 31
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Salwa, & Kumar, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.007 · Cited by 33
Yan, H., Feng, L., & Li, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s380612 · Cited by 35
“…and bapineuzumab, which target Aβ clearance, has raised doubts among scholars regarding the effectiveness of Aβ as a [55] ( Continued ) [87] 89–91 Currently, there is a growing interest among researchers in investigating the inhibition of Tau protein phosphorylation and aggregation as a…”
BackgroundAlzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 35
APP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway
Cheng, N., Jiao, S., Gumaste, A., Bai, L., & Belluscio, L. (2016) · eNeuro · doi:10.1523/eneuro.0150-16.2016 · Cited by 31
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.